Talis Biomedical Corporation

OTCPK:TLIS 주식 보고서

시가총액: US$3.0m

Talis Biomedical 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rob Kelley

최고 경영자

US$1.0m

총 보상

CEO 급여 비율54.1%
CEO 임기2.8yrs
CEO 소유권0.04%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간2.8yrs

최근 관리 업데이트

Recent updates

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Aug 16
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Talis Biomedical reports Q2 results

Aug 02

Talis Biomedical Aims For Manufacturing Turnaround

Mar 17

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Feb 08
Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18
News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14
Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

CEO 보상 분석

Rob Kelley 의 보수는 Talis Biomedical 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$51m

Mar 31 2024n/an/a

-US$57m

Dec 31 2023US$1mUS$551k

-US$62m

Sep 30 2023n/an/a

-US$75m

Jun 30 2023n/an/a

-US$86m

Mar 31 2023n/an/a

-US$98m

Dec 31 2022US$2mUS$525k

-US$113m

Sep 30 2022n/an/a

-US$115m

Jun 30 2022n/an/a

-US$127m

Mar 31 2022n/an/a

-US$165m

Dec 31 2021US$2mUS$322k

-US$192m

Sep 30 2021n/an/a

-US$208m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$2mUS$89k

-US$91m

보상 대 시장: Rob 의 총 보상 ($USD 1.02M )은 US 시장( $USD 654.40K ).

보상과 수익: Rob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Rob Kelley (52 yo)

2.8yrs

테뉴어

US$1,019,331

보상

Mr. Robert Kelley, also known as Rob, MBA, has been Chief Executive Officer and Director of Talis Biomedical Corporation since December 8, 2021 and served as its Chief Commercial Officer since September 20...


이사회 구성원

이름위치테뉴어보상소유권
Robert Kelley
CEO & Director2.8yrsUS$1.02m0.037%
$ 1.1k
Rustem Ismagilov
Co-Founder & Director11.3yrsUS$89.22k0.97%
$ 29.4k
Kimberly Popovits
Lead Independent Director2.8yrsUS$117.10k0.76%
$ 23.0k
Randal Scott
Independent Director8.7yrsUS$100.27k6.3%
$ 190.7k
Matthew Posard
Independent Director8.6yrsUS$99.27k0.23%
$ 6.9k
Heinrich Dreismann
Independent Director1.4yrsUS$34.18k0.015%
$ 454.8
Raymond Cheong
Director1.6yrsUS$45.29k0%
$ 0

2.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: TLIS 의 이사회경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.